Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05333276
Other study ID # TQB3602-AK105-I-01
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date July 29, 2022
Est. completion date May 2024

Study information

Verified date July 2023
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-programmed cell death protein 1 (PD-1) antibody.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 7
Est. completion date May 2024
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1 Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. - 2 Age = 18; Eastern Cooperative Oncology Group perfomance status score: 0-2; at least 3 months expected survival period. - 3 Subjects with relapse advanced malignant solid tumors clearly diagnosed by pathology and / or cytology, lack of conventional effective treatment methods, failure or relapse after treatment. - 4 Resolved acute effects of any prior therapy to baseline severity or Grade = 1 per CTCAE v5.0 except for AEs not constituting a safety risk by investigator judgment. - 5 Must have adequate organ and bone marrow function. - 6 Male and female patients of childbearing potential and at risk for pregnancy must agree to use two highly effective method(s) of contraception throughout the study and for at least 6 months after the last dose of assigned treatment. Exclusion Criteria: - 1 Subjects with other malignancies currently or suffered within 3 years. The following two conditions can be enrolled: other malignant tumors treated with a single operation to achieve disease-free survival (DFS) for 5 consecutive years; cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors[ Ta (non-invasive tumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)]; - 2 Sujects with multiple factors affecting oral administration; - 3 Subjets with unhealed toxicity above Grade 1 Common Terminology Criteria for Adverse Events Version 5.0 due to previous antitumor treatment; - 4 Subjects who have received major surgical treatment, open biopsy or obvious traumatic injury within 4 weeks before first administration; - 5 Subjects who have received surgery, chemotherapy, radiotherapy or other anticancer therapies 4 weeks before the first administration.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TQB3602 Capsule + AK105 Injection
TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.

Locations

Country Name City State
China Nong Yang Changsha Hunan
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose Limiting Toxicity (DLT) DLT will be assessed during the first 21 days of treatment for dose-escalation and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (21 days) of treatment. During the first 21 days
Primary Maximum tolerated dose (MTD) MTD is defined as the highest dosing schedule cohort level at which no more than 1 of 6 patients experience a Dose Limiting Toxicity (DLT). During the first 21 days
Primary Recommended phase II dose (RP2D) The RP2D was the maximum tolerated dose (MTD) or less. Up to Cycle 28 (Cycle Length= 21 days)
Secondary Number of patients with adverse events (AEs) and serious adverse events (SAEs) Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 From the time of informed consent signed to 90 days after the last dose
Secondary Progression-free survival (PFS) Defined as the time from the first dose of TQB3602 and AK105 to the first occurrence of disease progression or death from any cause. up to 2 years
Secondary Disease control rate (DCR) Defined as the proportion of subjects with CR (Complete response), PR (Partial response), or SD (Stable Disease). up to 2 years
Secondary Duration of Response (DOR) Defined as the time from first documented response to documented disease progression. up to 2 years
Secondary Overall survival (OS) OS is defined as the time between the date of first administration and the date of death due to any cause. A participant who has not died will be censored at the last known alive date. up to 5 years
See also
  Status Clinical Trial Phase
Completed NCT01213238 - Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab Phase 1
Recruiting NCT02160366 - Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
Completed NCT00379353 - The Effects of Thalidomide on Symptom Clusters Phase 2
Completed NCT00903708 - LY2275796 in Advanced Cancer Phase 1
Terminated NCT00499382 - Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging N/A
Completed NCT02459964 - Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain Phase 4
Completed NCT01430572 - Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients Phase 1
Completed NCT02561234 - A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01375114 - The Effects of Ginseng on Cancer-Related Fatigue Phase 2
Completed NCT01454804 - Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors Phase 1
Completed NCT01201694 - Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L) Phase 1
Completed NCT02801045 - Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient N/A
Completed NCT02873975 - A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency Phase 2
Completed NCT01983969 - Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Phase 1/Phase 2
Completed NCT02272595 - Rational Therapeutics Based on Matched Tumor and Normal Tissue
Active, not recruiting NCT01999491 - A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma Phase 1
Recruiting NCT03375983 - Plasmodium Immunotherapy for Advanced Cancers Phase 1/Phase 2
Completed NCT02571036 - A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies Phase 1
Withdrawn NCT01608139 - Study of Curcumin, Vorinostat, and Sorafenib Phase 1
Completed NCT01024166 - Patient-Reported Outcomes-Based Palliative and Hospice Care Practice: A Usability Study N/A